Study: NCT06076837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: platinum-based drug indicated for the treatment of advanced cancers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: platinum-based drug indicated for the treatment of advanced cancers